VEGFA and neoplasm: PDX samples HCI-001 and HCI-002, which were Bevacizumab-insensitive but benefitted from the combination of an Hsp90 inhibitor with the VEGF drug when assaying tumour growth (Fig. 1a,b) and blood vessel formation (Supplementary Fig. 1A,B), yielded MVs with associated VEGF90K (Fig. 7b).